Market For Sanofi And Regeneron’s Zaltrap Could Be Limited
This article was originally published in The Pink Sheet Daily
Executive Summary
Zaltrap gains FDA approval in metastatic colorectal cancer but must compete against several strongly entrenched treatments – Avastin, Vectibix and Erbitux.